Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.5K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.5K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.0K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.0K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

392
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
392
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.4K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

9.4K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
9.4K
Antidotes01:17

Antidotes

1.2K
Antidotes are medicinal substances used to counteract the harmful effects of toxins or drugs in the body. They function in various ways, each uniquely designed to combat specific toxic compounds.
Specific antidotes operate by inhibiting the enzymes that control biochemical pathways, reducing the production of harmful metabolites.
An example of an antidote is atropine, which counteracts the detrimental effects of cholinesterase inhibitors. It achieves this by deactivating muscarinic receptors,...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Alpha-SPECT-Mini: A Small-Animal SPECT System based on Hyperspectral Compound-Eye Gamma Cameras.

IEEE transactions on radiation and plasma medical sciences·2026
Same author

Benchtop 2D multi-pinhole x-ray fluorescence imaging system using a high energy resolution pixelated cadmium zinc telluride detector.

Medical physics·2026
Same author

Single-Step Synthesis of Cs<sub>3</sub>Bi<sub>2</sub>I<sub>9</sub> Nanocrystals for Scalable Direct X‑ray Detectors.

ACS energy letters·2025
Same author

Elderly Man With Abdominal Pain.

Annals of emergency medicine·2025
Same author

Electronic tongue measurements as a predictor for sensory properties of vacuum-packed minced beef - A preliminary study.

Meat science·2024
Same author

The need to reconfigure consistency and variability to best manage changing flood risks in Aotearoa-New Zealand.

Journal of the Royal Society of New Zealand·2024
Same journal

Palliative Therapy for Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Ablative Therapies for Liver Tumors.

Hematology/oncology clinics of North America·2026
Same journal

Pathology of Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Minimally Invasive Surgery for Liver and Biliary Tract Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Surgical Considerations for Primary Liver Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Systemic Therapy for Biliary and Liver Neoplasms: Chemotherapy and Immunotherapy.

Hematology/oncology clinics of North America·2026
See all related articles

Related Experiment Video

Updated: Feb 20, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.4K

Antithrombotic Reversal Agents.

Matthew D Wilson1, Jonathan E Davis1

  • 1Department of Emergency Medicine, Georgetown University Hospital, Washington Hospital Center, 110 Irving Street, NA 1177, Washington, DC 20010, USA.

Hematology/Oncology Clinics of North America
|October 29, 2017
PubMed
Summary
This summary is machine-generated.

Emergency physicians must quickly manage bleeding in patients on anticoagulants. Understanding various antithrombotic reversal agents is crucial for timely and effective treatment decisions in critical care settings.

Keywords:
AnticoagulateAntithrombotic reversal agentBleedingCoagulopathicEmergency departmentReversal options

More Related Videos

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
07:13

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Published on: May 24, 2024

1.0K
Prehospital Thrombolysis: A Manual from Berlin
05:52

Prehospital Thrombolysis: A Manual from Berlin

Published on: November 26, 2013

22.5K

Related Experiment Videos

Last Updated: Feb 20, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.4K
Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
07:13

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Published on: May 24, 2024

1.0K
Prehospital Thrombolysis: A Manual from Berlin
05:52

Prehospital Thrombolysis: A Manual from Berlin

Published on: November 26, 2013

22.5K

Area of Science:

  • Emergency Medicine
  • Pharmacology
  • Hematology

Background:

  • Anticoagulated patients presenting with active bleeding pose a significant challenge in emergency departments.
  • The increasing variety of antithrombotic agents complicates rapid evaluation and treatment decisions.
  • Emergency practitioners require up-to-date knowledge of these agents and their reversal strategies.

Purpose of the Study:

  • To highlight the complexities of managing actively bleeding anticoagulated patients.
  • To emphasize the need for emergency physicians to be familiar with diverse antithrombotic agents.
  • To outline the available reversal options for antithrombotic therapy.

Main Methods:

  • Review of current antithrombotic agents and their properties.
  • Discussion of reversal strategies and agents.
  • Focus on the emergency department setting.

Main Results:

  • Active bleeding in anticoagulated patients necessitates prompt intervention.
  • A wide array of antithrombotic drugs requires specialized knowledge for reversal.
  • Available reversal options include vitamin K, FFP, PCC, rFVIIa, platelets, and desmopressin.

Conclusions:

  • Emergency care for bleeding anticoagulated patients demands rapid assessment and treatment.
  • Familiarity with antithrombotic agents and their reversal is essential for emergency practitioners.
  • Timely administration of appropriate reversal agents can improve patient outcomes.